

1 **Epidemiology and risk factors of Japanese encephalitis in Taiwan, 2010–2022**

2 Jen-Yu Hsu^{1,2,3,*}, Chien-Ching Hung^{4,5,6}, Wan-Chin Chen², Tsung-Pei Tsou², Angela Song-En

3 Huang^{2,*}

4 ¹ Department of Occupational Medicine and Clinical Toxicology, Taipei Veterans General Hospital,
5 Taipei, Taiwan.

6 ² Centers for Disease Control, Ministry of Health and Welfare, Taipei, Taiwan.

7 ³ School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei,
8 Taiwan.

9 ⁴ Department of Tropical Medicine and Parasitology, National Taiwan University College of
10 Medicine, Taipei, Taiwan.

11 ⁵ Department of Internal Medicine, National Taiwan University Hospital and National Taiwan
12 University College of Medicine, Taipei, Taiwan.

13 ⁶ Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch, Yunlin,
14 Taiwan.

15

16 *Co-corresponding authors: Jen-Yu Hsu, b94401012@ntu.edu.tw; Angela Song-En Huang,

17 huang.songen@cdc.gov.tw

18

19 **Running head:** Japanese encephalitis in Taiwan during 2010–2022

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

20 **Keywords:** vector-borne infection; mosquito; *Culex tritaeniorhynchus*; immunization; vaccination

21 **Word counts:**

22 Abstract: 292

23 Author summary: 189

24 Text: 3,688

25 **Number of figures:** 2

26 **Number of tables:** 2

27 **Supplementary figure:** 1

28 **Supplementary data:** 1

29

30

31 **Abstract**

32 **Introduction:** Taiwan introduced a two-dose inactivated Japanese encephalitis (JE) mouse brain-
33 derived (JE-MB) vaccine into routine childhood immunization in 1968, with booster vaccination
34 implemented in 1974 and 1983. In 2017, JE-MB vaccine was replaced by a two-dose live-attenuated
35 chimeric vaccine (JE-CV). After implementation of JE vaccination programs, JE cases have shifted
36 from children to adults. In this study, we described the JE epidemiology and identify high-risk
37 groups to further inform vaccine policy.

38 **Methodology/Principal Findings:** We extracted data from Taiwan's notifiable disease surveillance
39 database, vital statistics, and employment statistics from 2010 to 2022. Diagnosis of JE was
40 confirmed by JE seroconversion, a four-fold increase in virus-specific antibodies, a positive JE viral
41 nucleic-acid test, or JE virus isolation. From 2010 to 2022, a total of 313 cases of JE were diagnosed,
42 resulting in an overall incidence rate of 0.10 cases per 100,000 person-years and a mortality rate of
43 0.006 per 100,000 population. Among these patients, 64% were male, and the median age was 51
44 years (range 0–82). Compared with people born in or after 1976 (vaccinated with four doses of JE-
45 MB vaccine or two doses of JE-CV), those born in or before 1962 (unvaccinated) and those born
46 during 1963–1975 (vaccinated with two or three doses of JE-MB vaccine) had a 4.2-fold (95%
47 confidence interval [CI] 3.0–5.7) and 5.9-fold (95% CI 4.3–8.1) higher risk of JE, respectively. The
48 relative risk of working in agriculture, forestry, fishing, or animal husbandry, compared to other
49 occupations, was 5.0 (95% CI 3.5–7.0).

50 **Conclusions/Significance:** In Taiwan, individuals born before 1976 and those employed in
51 agriculture, forestry, fishing, or animal husbandry had a higher risk of JE. We recommend JE
52 vaccination for people in these high-risk groups who have not been fully vaccinated or have an
53 unknown vaccination history.

54

55

56 **Author Summary**

57 The Japanese encephalitis (JE) virus is primarily transmitted through infected mosquito bites
58 between animals such as pigs and birds, with humans being the dead-end hosts. JE can lead to death
59 or long-term neurological or psychiatric complications. Vaccination is the most effective preventive
60 measure against JE. With the implementation of comprehensive immunization programs against JE
61 since 1960s, Taiwan has experienced a significant decline in the incidence and mortality rates of the
62 disease. This retrospective observational cohort study utilized Taiwan's national databases from 2010
63 to 2022 to investigate the epidemiology of JE and identify high-risk populations, thereby to inform
64 vaccine policy. A total of 313 JE cases were diagnosed among Taiwanese citizens with an incidence
65 rate of 0.10 cases per 100,000 person-years and a mortality rate of 0.006 per 100,000 population,
66 indicating consistently low incidence and mortality rates. Several factors were statistically
67 significantly associated with the occurrence of JE, including male gender, individuals born before
68 1976, residing outside the northern region, and working in occupations related to agriculture,
69 forestry, fishing, or animal husbandry. To prevent JE, it is recommended to offer vaccination to high-
70 risk populations who have not completed their immunization.

71

72

73 **Introduction**

74 Japanese encephalitis virus (JEV) is primarily transmitted among various animals, including
75 pigs and birds, through the bites of infected mosquitoes, particularly *Culex tritaeniorhynchus* [1, 2].
76 Humans, as the dead-end host, may become infected incidentally through the bites of infected
77 mosquitoes [1, 2]. Symptoms of JEV infection can vary from mild flu-like symptoms to encephalitis,
78 the latter being characterized by high fever, headache, neck stiffness, disorientation, coma, seizures,
79 and paralysis. About 20% of the patients with Japanese encephalitis (JE) died, and up to 50% of the
80 survivors suffered from long-term neurological or psychiatric sequelae [3, 4]. There is still no
81 specific antiviral treatment available for JE. Given that herd immunity may not necessarily work, the
82 most effective approach to preventing JE is personal vaccination or adopting measures to avoid
83 mosquito bites [5].

84 JE is a vaccine-preventable disease, and vaccination policies have successfully prevented
85 approximately one-third of annual JE cases worldwide, leaving around 50,000 to 100,000 cases each
86 year [5-7]. Vaccination has also played a crucial role in reducing JE-related deaths [3]. In Taiwan,
87 since the 1960s, the inactivated JE mouse brain-derived (JE-MB) vaccine, derived from the JEV
88 genotype III strain (Nakayama), has been included in the Expanded Program on Immunization for
89 children [8]. A study conducted in Taiwan between 1971 and 2000 found that a single dose of the
90 JE-MB vaccine can provide protection to over 80% of individuals against JE for up to 30 years, and
91 administering multiple doses can further decrease the incidence and mortality rates [9]. During the

92 2000s in Taiwan, the majority of JE patients were individuals who had not received the vaccine
93 previously [5]. However, since 2010, JEV genotype I has replaced genotype III as the dominant viral
94 strain in Taiwan [10], and the effectiveness of JE-MB vaccine against this different strain after more
95 than 30 years of vaccination has not been evaluated.

96 The risk of JE is also influenced by various other factors. Mosquitoes play a critical role in
97 exposing humans to JEV [11]. The abundance of mosquitoes and the spread of JEV are significantly
98 affected by multiple factors, including temperature, humidity, precipitation, altitude, land use,
99 agricultural practices, livestock and bird densities, and socioeconomic status [12-16]. In Taiwan, the
100 primary vector species for JEV transmission is *C. tritaeniorhynchus* [10], and the risk of JE is
101 associated with rising temperatures and specific humidity levels [13]. The eastern region of Taiwan
102 has reported a higher incidence of JE, but the underlying cause remains unknown [17, 18]. Pig farms
103 may pose a higher JE risk than wetlands due to the significantly higher rates of JEV infection in
104 mosquitoes from pig farms [10]. While mosquito-borne diseases have been recognized as
105 occupational diseases for individuals traveling to endemic areas [19], the knowledge may be lacking
106 in areas where they are prevalent. Studies examining JE in specific occupations have mainly relied
107 on questionnaire surveys [20] and descriptive epidemiology [21, 22], highlighting the need for more
108 analytical epidemiological studies.

109 Since there is currently no definitive method to control the vector, vaccination is considered an
110 effective approach to preventing JEV infection [23]. The objective of this study was to explore the

111 epidemiology of JE and identify the current high-risk groups, aiming to inform vaccination policies

112 in Taiwan.

113

114 **Materials and Methods**

115 *Study population and setting*

116 In Taiwan, JE has been categorized as a mandatory notifiable infectious disease since 1955, and
117 in 1965, the Centers for Disease Control (CDC) established laboratory testing methods to aid in the
118 diagnosis of JE. Clinicians were responsible for identifying patients suspected of having JE by
119 assessing symptoms such as fever, headache, neck stiffness, vomiting, acute psychosis (delirium,
120 confusion, etc.), disturbance of consciousness, abnormal muscle tone, focal neurological deficit, or
121 seizure. Subsequently, the medical staff at the hospital reported the patients' basic information and
122 clinical characteristics to the CDC, along with samples of blood, cerebrospinal fluid, or tissue to the
123 CDC for confirmation of the diagnosis. Upon the confirmation of a case, local health authorities
124 promptly initiated a comprehensive investigation into the affected individuals, including inquiries
125 into their residential and occupational environments. Furthermore, information was provided to
126 reinforce hygiene education among individuals at risk in the surrounding areas.

127 In order to further decrease the incidence and mortality rates of JE, Taiwan incorporated the JE
128 vaccine into its Expanded Program on Immunization for children in 1968. Initially, children aged 3
129 years or younger received two doses of JE-MB vaccine [8]. By 1974, the vaccination regimen was
130 expanded to three doses, with a booster dose of JE-MB vaccine administered one year after the initial
131 two doses [8]. Additionally, starting in 1983, children in their first year of elementary school
132 received an extra booster dose of JE-MB vaccine [8, 24]. Since 2017, traditional vaccines have been

133 replaced by a live-attenuated chimeric vaccine (JE-CV), which is administered in two doses with a 1-
134 year interval. This vaccine implementation has effectively prevented JE and resulted in a shift of JE
135 occurrences from children to adults. Between 1968 and 2012, the incidence rate of JE has declined
136 significantly from 2.05 to 0.12 cases per 100,000 person-years [8, 17]. Prior to 1966, over 95% of JE
137 patients were aged 20 years or younger, whereas after 1998, over 90% were aged more than 20 years
138 [8, 25]. Moreover, the mortality rate has also been decreasing year by year [17].

139

140 ***Study procedure***

141 This retrospective observational cohort study was conducted in Taiwan utilizing nationwide
142 databases from January 2010 to December 2022. Our investigation involved the utilization of the
143 National Infectious Disease Reporting System (NIRDS) archive, which is maintained by the CDC.
144 This allowed us to gather comprehensive information pertaining to laboratory-confirmed JE cases,
145 including details such as sex, birth date, residence, environmental exposure, occupational category,
146 symptoms, signs, date of diagnosis, and, if applicable, death date. To facilitate the identification and
147 comparison of risk factors, we also obtained data on the sex, birth cohort, residence, and
148 occupational category of all Taiwanese citizens throughout the duration of the study. To obtain these
149 data, we utilized two reliable sources—the nationwide Population Data published by the Department
150 of Household Registration, the Ministry of the Interior, and the Employment and Unemployment
151 Statistics Enquiry System, managed by the Directorate General of Budget, Accounting, and

152 Statistics.

153

154 ***Laboratory investigations***

155 The central laboratory of Taiwan CDC is well-equipped to conduct essential diagnostic tests for
156 JE, encompassing serological diagnosis, molecular diagnosis, and virus isolation using cell culture.
157 In the past, the hemagglutination inhibition assay was employed to identify a four-fold increase in
158 plasma antibodies against both JE and dengue fever, with dengue antibody test results serving as a
159 negative control to minimize the potential for cross-reactivity. However, a more specific diagnostic
160 method for JE was developed by the laboratory in 1998. This method utilized an envelope- and
161 membrane-specific capture IgM and IgG enzyme-linked immunosorbent assay (ELISA) to detect
162 seroconversion, which subsequently became the primary approach for serological diagnosis. Starting
163 in 2001, molecular diagnosis became another valuable tool for detecting JEV RNA in blood,
164 cerebrospinal fluid, or tissue through real-time polymerase chain reaction. Additionally, virus
165 isolation through cell culture was another diagnostic technique employed, which involved observing
166 characteristic cytopathic effects and detecting its antigen using an indirect immunofluorescence
167 assay. At least one of the three diagnostic methods (serological diagnosis, molecular diagnosis, and
168 virus isolation through cell culture) was necessary to confirm case of JEV infection.

169

170 ***Data collection and definitions***

171 Between 2010 and 2022, laboratory-confirmed JE cases were recorded monthly, from January to
172 December. All patients and/or family members were thoroughly inquired about a range of symptoms,
173 including fever, headache, neck stiffness, vomiting, acute psychosis, disturbance of consciousness,
174 movement disorder, focal neurological deficit, seizures, and any other unlisted symptoms. Mortality
175 data were collected and linked to the NIDRS through mandatory reporting. The observation period
176 for mortality was extended to one year following the onset of symptoms or until May 29, 2023.

177 The laboratory-confirmed cases of JE, as well as the entire Taiwanese population, underwent a
178 grouping based on sex at birth and birth date. Males and females were distinguished, and age
179 categories were established to cover different age ranges: juveniles (<18 years), adults (18–64 years),
180 and the elderly (≥ 65 years). Furthermore, this study classified individuals into three groups based on
181 their birth year: those born in or before 1962, those born between 1963 and 1975, and those born in
182 or after 1976. These groups were identified as follows: Cohort 1, consisting of unvaccinated
183 individuals; Cohort 2, including those who received two or three doses of JE-MB vaccine; and
184 Cohort 3, comprising those who received either four doses of JE-MB vaccine or two doses of JE-CV
185 vaccine.

186 The residences were divided into four regions according to the National Development Council's
187 classification, based on cities or counties. The northern region consisted of Taipei, New Taipei,
188 Keelung, Taoyuan, Hsinchu, Yilan, Lianjiang, and Kinmen. The central region included Miaoli,
189 Taichung, Nantou, Changhua, and Yunlin. The southern region encompassed Chiayi, Tainan,

190 Kaohsiung, Pingtung, and Penghu. The eastern region comprised Hualien and Taitung (Fig S1).
191 Through the investigations, potential sources of exposure for JE patients, such as pig farms and
192 pigeon coops within a one to five-kilometer radius, as well as rice paddy fields, were identified [26,
193 27]. Individuals working in agriculture, forestry, fisheries, or animal husbandry were identified,
194 while those employed in other industries, such as manufacturing and services, were classified as
195 "other occupations."

196

197 ***Statistical analysis***

198 The incidence and mortality rates of JE were calculated as the total number of occurrences
199 divided by the total person-years of follow-up. For demographic and clinical characteristics,
200 quantitative variables were analyzed by calculating medians and ranges, while categorical variables
201 were examined by calculating numbers and percentages. To assess the relative risk (RR) for each
202 category of sex, age, birth cohort, residence, and occupation, the risk of each group was compared
203 with the risk of all the other groups. The 95% confidence interval was estimated using the Poisson
204 distribution. Statistical analyses were performed using Statistical Analysis Software version 9.4
205 (SAS Institute, Cary, NC, USA).

206

207 ***Ethics Statement***

208 This study was approved by the Institutional Review Board of Centers for Disease Control,

209 Ministry of Health and Welfare, Taiwan (No. TwCDCIRB112110). All information was anonymized

210 and analyzed as secondary data. Informed consent was waived due to the retrospective design.

211

212 **Results**

213 *Incidence and mortality rates*

214 From 2010 to 2022, a total of 313 Taiwanese citizens were diagnosed with JE through laboratory
215 confirmation. The median annual number of JE cases was 22, ranging from 15 to 35 cases. The
216 overall incidence rate was 0.10 cases per 100,000 person-years, which varied between 0.06 and 0.15
217 across the 13 study years. However, no significant change in the incidence rate was observed over
218 the years (Fig 1A). The months of June (41%) and July (32%) had the highest occurrence of JE,
219 followed by May (12%) and August (6%). Notably, there were no JE cases diagnosed during the
220 months of December, January, February, March, and April (Fig 1B).

221 Among the 313 JE patients, fever (80%) and mental status changes (69%) were the most
222 prevalent symptoms, followed by headaches (34%), acute psychosis (22%), and neck stiffness
223 (18%). Less common symptoms included vomiting, seizures, movement disorders, and focal
224 neurological deficits. The overall mortality rate was low, with an estimated rate of 0.006 per 100,000
225 population per year (Fig 1A). The case fatality rate was 5.4%, with 17 deaths occurring within one
226 year of diagnosis. Of the 17 fatal cases, 29% occurred within 30 days, while 76% and 88% occurred
227 within 90 and 180 days of diagnosis, respectively.

228

229 *Sex, age, and birth cohort*

230 Among the 313 patients diagnosed with JE, males accounted for 64% of the cases, with females

231 comprising the remaining 36%. The overall incidence rate for males (0.13 per 100,000 person-years)
232 was higher than that for females (0.07 per 100,000 person-years) (Fig 2A). The median age of the JE
233 patients was 51 years (range, 0 to 82). Only 2%, were juveniles, while the majority were adults,
234 making up 87% of the cases, and the remaining 11% were elderly individuals. The overall incidence
235 rates for JE among juveniles, adults, and the elderly were 0.01, 0.13, and 0.08 per 100,000 person-
236 years, respectively (Fig 2B). Throughout the study period, the proportions of all JE patients
237 diagnosed in Cohorts 1, 2, and 3 were 41%, 41%, and 18%, respectively. Cohorts 1 and 2 had higher
238 overall incidence rates of 0.15 and 0.21 cases per 100,000 person-years, respectively, while Cohort 3
239 had the lowest rate of 0.04 cases per 100,000 person-years (Fig 2C).

240

241 ***Residence, environmental exposure, and occupational category***

242 The northern, central, southern, and eastern regions accounted for 22%, 28%, 44%, and 6% of
243 the JE cases diagnosed, respectively, with corresponding incidence rates of 0.05, 0.12, 0.17, and 0.27
244 per 100,000 person-years (Fig 2D). The cities or counties with the highest incidence rates were
245 Hualien in the eastern region, Nantou in the central region, Pingtung and Chiayi in the southern
246 region (excluding sparsely populated outlying islands) (Fig 2E). The investigations conducted by
247 local health authorities revealed that 60% of the JE patients had exposure to pigs, 45% had exposure
248 to pigeons, and 60% had exposure to rice paddy fields. It was observed that 89% of the JE patients
249 had exposure to at least one of the aforementioned risk factors. Of the JE patients, 68% were

250 employed, of whom 20% were employed in agriculture, forestry, fishing, or animal husbandry
251 industries, and the remaining 80% were engaged in other occupations. The incidence rates among
252 these two groups were 0.59 and 0.12 per 100,000 person-years, respectively (Figure 2E).

253

254 ***Risk factors of Japanese encephalitis***

255 This study identified several significant factors associated with JE, including sex, age, birth
256 cohort, residence, and occupation (Table 2). Males had a higher risk compared to females (RR 1.8,
257 95% CI 1.4–2.3). Adults and elderly individuals were at significantly higher risk compared to
258 juveniles (RR 11.1, 95% CI 5.0–25.0 and RR 7.3, 95% CI 3.1–17.4, respectively). Cohorts 1 and 2
259 had higher risks compared to Cohort 3 (RR 4.2, 95% CI 3.0–5.7 and RR 5.9, 95% CI 4.3–8.1,
260 respectively). People residing in central, southern, and eastern Taiwan had higher risks compared to
261 those living in northern Taiwan (RR 2.4, 95% CI 1.7–3.3, RR 3.4, 95% CI 2.6–4.6, and RR 5.4, 95%
262 CI 3.3–9.0, respectively). Furthermore, workers in agriculture, forestry, fishing, or animal husbandry
263 had a higher risk compared to individuals in other occupations (RR 5.0, 95% CI 3.5–7.0).

264

265 **Discussion**

266 From 2010 to 2022, Taiwan experienced consistently low incidence rate of JE and its associated
267 mortality. However, certain factors were identified as being associated with a higher incidence of JE
268 in Taiwan, which included male gender, individuals born before 1976, residing outside the northern
269 region, and working in occupations related to agriculture, forestry, fishing, or animal husbandry.

270 Compared to other countries in the Asia-Pacific region, Taiwan has made significant strides in
271 combating JE [28]. Similar to South Korea and Japan, Taiwan has successfully reduced the
272 occurrence and death rates of JE [17, 28-30]. Various factors have contributed to this achievement,
273 including urbanization, reduced rice paddy field sizes, relocation of pig farms, and the use of
274 pesticides to control mosquito vectors. However, the most crucial factor has been the implementation
275 of comprehensive immunization programs against JE. Initially introduced in the 1960s, the program
276 administered two or three doses of the JE-MB vaccine, resulting in a vaccination rate of 80% or
277 higher. Subsequently, the policy was updated to administration of four doses, with an outstanding
278 vaccination rate of 95%. As a result, Taiwan has maintained a stable JE incidence rate of 0.10 cases
279 per 100,000 person-years over the past three decades [8], with a record-low death rate of 0.006 per
280 100,000 population per year in the past decade [17]. The success of the JE immunization program
281 has also highlighted the crucial role of vaccination in reducing fatalities [3], as evidenced by
282 Taiwan's one-year case fatality rate of 5.4%, which was lower than those in the previous records
283 [17]. However, it is important to acknowledge the potential for a slight increase in delayed deaths

284 resulting from long-term neurological or psychiatric sequelae [4].

285 In Taiwan, different numbers of vaccine doses may result in varying levels of protection. Cohort
286 1, with a higher likelihood of mosquito exposure during childhood, primarily acquired JEV infection
287 naturally. On the other hand, Cohorts 2 and 3 obtained antibodies through various vaccination
288 programs implemented following environmental changes. During the follow-up period, Cohorts 1
289 and 2 exhibited significantly higher incidence rates of JE compared to Cohort 3. This could be
290 attributed to lower antibody levels in Cohorts 1 and 2, unlike nearly all people of Cohort 3 who had
291 undergone complete vaccination against JE and might continue to have higher antibody levels [8].
292 Furthermore, Cohort 2 had a higher incidence rate than Cohort 1, potentially due to incomplete
293 vaccination that might fail to provide the same long-lasting immunity as natural infection. Another
294 factor to consider was the vaccines developed for JEV genotype III might have reduced effectiveness
295 against JEV genotype I [31]. Overall, this study suggested that individuals who had not received four
296 doses of JE-MB vaccine exhibited significantly higher incidence rates than those who had received
297 four doses of JE-MB vaccine or two doses of JE-CV. Our findings may provide additional insights
298 into previously limited information on vaccine effectiveness at the population level [4, 18].

299 There were several other factors that contributed to the occurrence of JE in Taiwan. Men were
300 found to have a higher risk than women, likely due to their involvement in outdoor activities.
301 Nationwide data between 2010 and 2022 revealed that men had an average labor force participation
302 rate of 67%, while women's rate was approximately 51%. JE was predominantly prevalent during

303 June and July, influenced not only by the favorable temperature and humidity for mosquito growth
304 but also by pig breeding [13, 17]. The agriculture, forestry, fishing, and animal husbandry industries
305 posed a higher risk of disease transmission, likely due to increased exposure to pigs, birds, and
306 farmland. However, in Taiwan, an endemic area for JEV infection, criteria for determining whether
307 JEV infections in individuals residing in such areas are qualified as occupational diseases have not
308 been established. This study revealed the link between JE and occupational factors by identifying a
309 notable number of JE patients in Taiwan over the past 13 years who were involved in specific
310 occupations.

311 The incidence of JE in Taiwan exhibited regional variations, with the eastern region having the
312 highest incidence, followed by the southern and central regions, while the northern region had the
313 lowest incidence. Previous research has indicated that the seropositive rate of Cohort 2 sampled in
314 eastern Taiwan was lower [32], suggesting a lower vaccination coverage during the early stages of
315 the vaccination program in that particular region. Moreover, the distribution of industries varied
316 across different regions, with 80% of agriculture and animal husbandry workers concentrated in the
317 central, southern, and eastern regions. In these regions, the proportion of such workers was 5-15
318 times higher than in the northern region, with the eastern region having the highest proportion. As a
319 result, individuals residing in the eastern region of Taiwan were likely at a higher risk of contracting
320 JEV infection due to a lower vaccine coverage and a greater proportion of agriculture and animal
321 husbandry workers.

322 The production of JE-MB vaccine was discontinued due to safety concerns and the requirement
323 for multiple doses, despite its immunogenicity. In contrast, JE-CV has been shown to be safe, highly
324 immunogenic, and capable of providing long-lasting immunity. Notably, a single dose of JE-CV is
325 sufficient to confer protective immunity, comparable to the effect of three doses of JE-MB vaccine in
326 adults [33]. In light of the unavailability of JE-MB vaccine, JE-CV could be considered as a
327 replacement or used as a booster or catch-up regimen [25]. However, it is important to note that,
328 similar to JE-MB vaccine, JE-CV is derived from the JEV genotype III strain (SA14-14-2). While
329 some partial cross-protection between genotype I and III strains has been observed in mice, the
330 effectiveness of JE-CV against the genotype I strain was lower than its effectiveness against the
331 genotype III strain, as demonstrated in both mice and swine [31, 34]. Further analysis of vaccine
332 effectiveness in humans would be necessary, and the development of a bivalent vaccine could be a
333 potential alternative strategy for vaccination against JE.

334

335 **Limitations**

336 There were several limitations to this study. First, the incidence and mortality of JE may have
337 been underestimated as the awareness of JE and decision to notify suspected cases was at the
338 discretion of attending physicians. However, since notification for laboratory confirmation was
339 easily accessible and free of charge in Taiwan, the likelihood of missing to notify suspected cases
340 was relatively low. Second, there might be inaccuracies in the established databases. We did not have

341 vaccination records for all individuals, and our evaluation of vaccine effectiveness relied solely on
342 the risk of the birth cohort. Furthermore, the scope of investigation by local health authorities
343 regarding exposure to pigs, pigeons, and rice paddy fields might not have been extensive enough
344 given the long-distance migration ability of *C. tritaeniorhynchus* [35]. To address this, we assessed
345 the occupational risk of agriculture, forestry, fishing, and animal husbandry workers to evaluate the
346 exposure risk. Third, it is important to note that factors identified as high risk for JE do not
347 necessarily prove causation. Possible risk factors were not simultaneously evaluated in one model,
348 and future studies should consider adjusting for confounding factors. Finally, it should be
349 emphasized that the prevalent JEV strains in Taiwan after 2010 were genotype I. Therefore, the
350 findings of this study may not be generalizable to other countries, and policies should be adjusted
351 based on research results relevant to the specific region or country.

352

353 **Conclusions**

354 JE is a life-threatening disease that should not be underestimated, despite its low incidence and
355 mortality rates in Taiwan. It poses a particular risk to individuals born before 1976 and those
356 employed in agriculture, forestry, fishing, or animal husbandry. To prevent JE, vaccination should be
357 offered to high-risk populations who have not received complete immunization.

358

359 **Acknowledgments**

360 The authors would like to thank all staff in the Taiwan government agencies for the

361 investigations and data preservation.

362

363 **References**

- 364 1. Suresh KP, Nayak A, Dhanze H, Bhavya AP, Shivamallu C, Achar RR, et al. Prevalence of
365 Japanese encephalitis (JE) virus in mosquitoes and animals of the Asian continent: A systematic
366 review and meta-analysis. *J Infect Public Health*. 2022;15(9):942-9. Epub 2022/08/02. doi:
367 10.1016/j.jiph.2022.07.010. PubMed PMID: 35914358.
- 368 2. Ladreyt H, Durand B, Dussart P, Chevalier V. How Central Is the Domestic Pig in the
369 Epidemiological Cycle of Japanese Encephalitis Virus? A Review of Scientific Evidence and
370 Implications for Disease Control. *Viruses*. 2019;11(10). Epub 2019/10/18. doi: 10.3390/v11100949.
371 PubMed PMID: 31618959; PubMed Central PMCID: PMC6832429.
- 372 3. Cheng Y, Tran Minh N, Tran Minh Q, Khandelwal S, Clapham HE. Estimates of Japanese
373 Encephalitis mortality and morbidity: A systematic review and modeling analysis. *PLoS Negl Trop*
374 *Dis*. 2022;16(5):e0010361. Epub 2022/05/26. doi: 10.1371/journal.pntd.0010361. PubMed PMID:
375 35613183; PubMed Central PMCID: PMC69173604.
- 376 4. Chen HY, Yang CY, Hsieh CY, Yeh CY, Chen CC, Chen YC, et al. Long-term neurological
377 and healthcare burden of adults with Japanese encephalitis: A nationwide study 2000-2015. *PLoS*
378 *Negl Trop Dis*. 2021;15(9):e0009703. Epub 2021/09/15. doi: 10.1371/journal.pntd.0009703.
379 PubMed PMID: 34520457; PubMed Central PMCID: PMC68486099 following competing
380 interests: Chung-Chih Lai and Rebecca Claire Harris are the employees of Sanofi Pasteur and may
381 hold shares and/or stock options in the company. The other authors have no competing interests to
382 declare.
- 383 5. Quan TM, Thao TTN, Duy NM, Nhat TM, Clapham H. Estimates of the global burden of
384 Japanese encephalitis and the impact of vaccination from 2000-2015. *Elife*. 2020;9. Epub
385 2020/05/27. doi: 10.7554/eLife.51027. PubMed PMID: 32450946; PubMed Central PMCID:
386 PMC67282807.
- 387 6. Moore SM. The current burden of Japanese encephalitis and the estimated impacts of
388 vaccination: Combining estimates of the spatial distribution and transmission intensity of a zoonotic
389 pathogen. *PLoS Negl Trop Dis*. 2021;15(10):e0009385. Epub 2021/10/14. doi:
390 10.1371/journal.pntd.0009385. PubMed PMID: 34644296; PubMed Central PMCID:
391 PMC68544850.
- 392 7. Campbell GL, Hills SL, Fischer M, Jacobson JA, Hoke CH, Hombach JM, et al. Estimated
393 global incidence of Japanese encephalitis: a systematic review. *Bull World Health Organ*.
394 2011;89(10):766-74, 74a-74e. Epub 2011/11/16. doi: 10.2471/blt.10.085233. PubMed PMID:
395 22084515; PubMed Central PMCID: PMC3209971.
- 396 8. Hsu LC, Chen YJ, Hsu FK, Huang JH, Chang CM, Chou P, et al. The incidence of Japanese
397 encephalitis in Taiwan--a population-based study. *PLoS Negl Trop Dis*. 2014;8(7):e3030. Epub
398 2014/07/25. doi: 10.1371/journal.pntd.0003030. PubMed PMID: 25058573; PubMed Central
399 PMCID: PMC4109885.

- 400 9. Yang SE, Pan MJ, Tseng HF, Liao MY. The efficacy of mouse-brain inactivated Nakayama
401 strain Japanese encephalitis vaccine--results from 30 years experience in Taiwan. *Vaccine*.
402 2006;24(14):2669-73. Epub 2005/11/30. doi: 10.1016/j.vaccine.2005.10.054. PubMed PMID:
403 16314007.
- 404 10. Su CL, Yang CF, Teng HJ, Lu LC, Lin C, Tsai KH, et al. Molecular epidemiology of Japanese
405 encephalitis virus in mosquitoes in Taiwan during 2005-2012. *PLoS Negl Trop Dis*.
406 2014;8(10):e3122. Epub 2014/10/03. doi: 10.1371/journal.pntd.0003122. PubMed PMID: 25275652;
407 PubMed Central PMCID: PMCPMC4183467.
- 408 11. Oliveira ARS, Cohnstaedt LW, Strathe E, Hernández LE, McVey DS, Piaggio J, et al. Meta-
409 analyses of the proportion of Japanese encephalitis virus infection in vectors and vertebrate hosts.
410 *Parasit Vectors*. 2017;10(1):418. Epub 2017/09/09. doi: 10.1186/s13071-017-2354-7. PubMed
411 PMID: 28882172; PubMed Central PMCID: PMCPMC5590142.
- 412 12. Esser HJ, Mögling R, Cleton NB, van der Jeugd H, Sprong H, Stroo A, et al. Risk factors
413 associated with sustained circulation of six zoonotic arboviruses: a systematic review for selection of
414 surveillance sites in non-endemic areas. *Parasit Vectors*. 2019;12(1):265. Epub 2019/05/28. doi:
415 10.1186/s13071-019-3515-7. PubMed PMID: 31133059; PubMed Central PMCID:
416 PMCPMC6537422.
- 417 13. Lin CL, Chang HL, Lin CY, Chen KT. Seasonal Patterns of Japanese Encephalitis and
418 Associated Meteorological Factors in Taiwan. *Int J Environ Res Public Health*. 2017;14(11). Epub
419 2017/11/08. doi: 10.3390/ijerph14111317. PubMed PMID: 29109371; PubMed Central PMCID:
420 PMCPMC5707956.
- 421 14. Sarkar A, Aronson KJ, Patil S, Hugar LB, vanLoon GW. Emerging health risks associated with
422 modern agriculture practices: a comprehensive study in India. *Environ Res*. 2012;115:37-50. Epub
423 2012/04/07. doi: 10.1016/j.envres.2012.03.005. PubMed PMID: 22480534.
- 424 15. Kardena IM, Adi A, Astawa NM, O'Dea M, Laurence M, Sahibzada S, et al. Japanese
425 encephalitis in Bali, Indonesia: ecological and socio-cultural perspectives. *Int J Vet Sci Med*.
426 2021;9(1):31-43. Epub 2021/10/01. doi: 10.1080/23144599.2021.1975879. PubMed PMID:
427 34589543; PubMed Central PMCID: PMCPMC8451599.
- 428 16. Power GM, Vaughan AM, Qiao L, Sanchez Clemente N, Pescarini JM, Paixão ES, et al.
429 Socioeconomic risk markers of arthropod-borne virus (arbovirus) infections: a systematic literature
430 review and meta-analysis. *BMJ Glob Health*. 2022;7(4). Epub 2022/04/17. doi: 10.1136/bmjgh-
431 2021-007735. PubMed PMID: 35428678; PubMed Central PMCID: PMCPMC9014035.
- 432 17. Wu YC, Huang YS, Chien LJ, Lin TL, Yueh YY, Tseng WL, et al. The epidemiology of
433 Japanese encephalitis on Taiwan during 1966-1997. *Am J Trop Med Hyg*. 1999;61(1):78-84. Epub
434 1999/08/04. doi: 10.4269/ajtmh.1999.61.78. PubMed PMID: 10432061.
- 435 18. Chang YK, Chang HL, Wu HS, Chen KT. Epidemiological Features of Japanese Encephalitis in
436 Taiwan from 2000 to 2014. *Am J Trop Med Hyg*. 2017;96(2):382-8. Epub 2016/11/09. doi:
437 10.4269/ajtmh.16-0330. PubMed PMID: 27821699; PubMed Central PMCID: PMCPMC5303041.

- 438 19. Jansing PJ, Morrison A, Heggie TW, Küpper T. Tropical infections as occupational diseases –
439 labor inspectorate physicians’ aspects of a complex problem. *Health Promotion & Physical Activity*.
440 2021;15(2):21-8. doi: 10.5604/01.3001.0015.0505.
- 441 20. Dhakal S, Stephen C, Ale A, Joshi DD. Knowledge and practices of pig farmers regarding
442 Japanese encephalitis in Kathmandu, Nepal. *Zoonoses Public Health*. 2012;59(8):568-74. Epub
443 2012/05/17. doi: 10.1111/j.1863-2378.2012.01498.x. PubMed PMID: 22587420.
- 444 21. Tang XY, Xu BL, Guo WS, Li XL. [Surveillance and control of Japanese encephalitis in Henan
445 province, 1950 - 2008]. *Zhonghua Liu Xing Bing Xue Za Zhi*. 2009;30(9):923-6. Epub 2010/03/03.
446 PubMed PMID: 20193229.
- 447 22. Tang XY, Kang K, Shang SY, Xu C, Li XL, Ma HX, et al. [Epidemic characteristics and viral
448 antibody level among healthy people of Japanese B encephalitis in Henan province in 2010].
449 *Zhonghua Yu Fang Yi Xue Za Zhi*. 2012;46(10):888-91. Epub 2013/02/01. PubMed PMID:
450 23363861.
- 451 23. Wilson AL, Dhiman RC, Kitron U, Scott TW, van den Berg H, Lindsay SW. Benefit of
452 insecticide-treated nets, curtains and screening on vector borne diseases, excluding malaria: a
453 systematic review and meta-analysis. *PLoS Negl Trop Dis*. 2014;8(10):e3228. Epub 2014/10/10. doi:
454 10.1371/journal.pntd.0003228. PubMed PMID: 25299481; PubMed Central PMCID:
455 PMC4191944.
- 456 24. Fischer M, Lindsey N, Staples JE, Hills S. Japanese encephalitis vaccines: recommendations of
457 the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep*. 2010;59(Rr-
458 1):1-27. Epub 2010/03/13. PubMed PMID: 20224546.
- 459 25. Lee PI, Huang YC, Hwang KP, Liu CC, Chiu CH, Chen PY, et al. Recommendations for the
460 use of Japanese encephalitis vaccines. *Pediatr Neonatol*. 2020;61(1):3-8. Epub 2019/12/25. doi:
461 10.1016/j.pedneo.2019.11.009. PubMed PMID: 31870559.
- 462 26. Tuno N, Tsuda Y, Takagi M. How Zoophilic Japanese Encephalitis Vector Mosquitoes Feed on
463 Humans. *J Med Entomol*. 2017;54(1):8-13. Epub 2017/01/14. doi: 10.1093/jme/tjw165. PubMed
464 PMID: 28082626.
- 465 27. Hameed M, Wahaab A, Nawaz M, Khan S, Nazir J, Liu K, et al. Potential Role of Birds in
466 Japanese Encephalitis Virus Zoonotic Transmission and Genotype Shift. *Viruses*. 2021;13(3). Epub
467 2021/03/07. doi: 10.3390/v13030357. PubMed PMID: 33668224; PubMed Central PMCID:
468 PMC7996159.
- 469 28. Wang H, Liang G. Epidemiology of Japanese encephalitis: past, present, and future prospects.
470 *Ther Clin Risk Manag*. 2015;11:435-48. Epub 2015/04/08. doi: 10.2147/tcrm.S51168. PubMed
471 PMID: 25848290; PubMed Central PMCID: PMC4373597.
- 472 29. Kwak BO, Hong YJ, Kim DH. Changes in age-specific seroprevalence of Japanese encephalitis
473 virus and impact of Japanese encephalitis vaccine in Korea. *Clin Exp Pediatr*. 2022;65(3):108-14.
474 Epub 2021/10/01. doi: 10.3345/cep.2020.01984. PubMed PMID: 34592804; PubMed Central
475 PMCID: PMC8898622.

- 476 30. Arai S, Matsunaga Y, Takasaki T, Tanaka-Taya K, Taniguchi K, Okabe N, et al. Japanese
477 encephalitis: surveillance and elimination effort in Japan from 1982 to 2004. *Jpn J Infect Dis.*
478 2008;61(5):333-8. Epub 2008/09/23. PubMed PMID: 18806337.
- 479 31. Fan YC, Chen YY, Chen JM, Huang C, Huang M, Chiou SS. Effectiveness of Live-Attenuated
480 Genotype III Japanese Encephalitis Viral Vaccine against Circulating Genotype I Viruses in Swine.
481 *Viruses.* 2022;14(1). Epub 2022/01/23. doi: 10.3390/v14010114. PubMed PMID: 35062317;
482 PubMed Central PMCID: PMC8778556.
- 483 32. Hsu LC, Wu YC, Lin SR, King CC, Ho MS, Lu CF, et al. [Seroepidemiology of Japanese
484 encephalitis viral infection among 3-6 years old children from mountainous and plains townships
485 located in the northern, central, southern and eastern Taiwan]. *Zhonghua Min Guo Wei Sheng Wu Ji*
486 *Mian Yi Xue Za Zhi.* 1997;30(3):194-206. Epub 1997/08/01. PubMed PMID: 10592824.
- 487 33. Appaiahgari MB, Vrati S. IMOJEV(®): a Yellow fever virus-based novel Japanese encephalitis
488 vaccine. *Expert Rev Vaccines.* 2010;9(12):1371-84. Epub 2010/11/26. doi: 10.1586/erv.10.139.
489 PubMed PMID: 21105774.
- 490 34. Wei J, Wang X, Zhang J, Guo S, Pang L, Shi K, et al. Partial cross-protection between Japanese
491 encephalitis virus genotype I and III in mice. *PLoS Negl Trop Dis.* 2019;13(8):e0007601. Epub
492 2019/08/03. doi: 10.1371/journal.pntd.0007601. PubMed PMID: 31374086; PubMed Central
493 PMCID: PMC6693775.
- 494 35. Arai S, Kuwata R, Higa Y, Maekawa Y, Tsuda Y, Roychoudhury S, et al. Two hidden taxa in
495 the Japanese encephalitis vector mosquito, *Culex tritaeniorhynchus*, and the potential for long-
496 distance migration from overseas to Japan. *PLoS Negl Trop Dis.* 2022;16(6):e0010543. Epub
497 2022/07/01. doi: 10.1371/journal.pntd.0010543. PubMed PMID: 35771889; PubMed Central
498 PMCID: PMC9278767.

499

500

501 **Supporting information**

502 S1 Fig. The distribution map of cities and counties in Taiwan. (TIF)

503 S1 Data. (XLSX)

504 Fig 1A. The incidence and mortality rates of Japanese encephalitis (n = 313).

505 Fig 1B. The incidence rate of Japanese encephalitis by month (n = 313).

506 Fig 2A. The incidence rate of Japanese encephalitis by sex (n = 313).

507 Fig 2B. The incidence rate of Japanese encephalitis by age (n = 313).


508 Fig 2C. The incidence rate of Japanese encephalitis by birth year (n = 313).

509 Fig 2D. The incidence rate of Japanese encephalitis by region of residence (n = 313).

510 Fig 2E. The incidence rate of Japanese encephalitis by city or county of residence (n = 313).


511 Fig 2F. The incidence rate of Japanese encephalitis by occupation (n = 206).

Fig 1. (A) The incidence and mortality rates of Japanese encephalitis ($n = 313$). (B) The incidence rate of Japanese encephalitis by month ($n = 313$).




*Data is available in S1 Data file.


Fig 2. The incidence rate of Japanese encephalitis by (A) sex ($n = 313$), (B) age ($n = 313$), (C) birth year ($n = 313$), (D) region of residence ($n = 313$), (E) and city/county of residence ($n = 313$) (F) occupation ($n = 206$).



(B)



(C)




(D)

medRxiv preprint doi: <https://doi.org/10.1101/2023.05.30.23290705>; this version posted June 1, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).


Incidence (per 100,000 person-years)  0.05  0.12  0.17  0.27

(E)

medRxiv preprint doi: <https://doi.org/10.1101/2023.05.30.23290705>; this version posted June 1, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).



(F)



* Fig 2D and Fig 2E were generated using Statistical Analysis Software version 9.4 (SAS Institute, Cary, NC, USA). The link to the base layer of the map is: <https://data.gov.tw/dataset/7442>.

* Data is available in S1 Data file.